Join the Oncology Voice Network. Join for Free
What Makes KOLs Tick
Key Opinion Leaders KOL engagement strategies proactive MSL techniques rare disease MSL roles hybrid interaction post-COVID

What Makes KOLs Tick


Share This Article


Summary

In this episode, Deanna Murray joins to delve into the intricacies of engaging with Key Opinion Leaders (KOLs). The discussion begins with understanding KOL motivations and the importance of aligning with their needs. Deanna highlights the significance of proactive strategies, effective pre-call planning, and questioning techniques. The conversation explores innovative approaches to KOL engagement, emphasizing problem-solving and tailoring presentations. The role of MSLs in rare diseases and adapting to hybrid interactions post-COVID are also covered. The episode concludes with performance enhancement tips and an acknowledgment of the sponsor, High Five Challenge.

Deanna Murray, MSL Team Lead at Sarepta Pharmaceuticals discusses what makes KOLs tick and how to be a more effective MSL

Deanna shares…

πŸ‘‰ How to be a more proactive MSL vs reactive

πŸ‘‰ What questions MSLs should be asking their KOLs

πŸ‘‰ Why pre-call planning is so important

πŸ‘‰ How to determine WHAT you should be presenting to your KOLs

πŸ‘‰ Creative ways to get face time with your KOLs

Click for Source
Key Opinion Leaders, KOL engagement strategies, proactive MSL techniques, rare disease MSL roles, hybrid interaction post-COVID

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Podcast
The 3 β€œKnows” of Effective Scientific Communication
Partner Avatar MSL Talk: Tom Caravela, Linda Taylor

The 3 β€œKnows” of Effective Scientific Communication

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN